Futura Medical Share Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Futura Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Futura Medical stock.
View analyst ratings for Futura Medical or view top-rated stocks.

Wall Street analysts have given Futura Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Futura Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Futura Medical is scheduled to release its next quarterly earnings announcement on Tuesday, September 14th 2021.
View our earnings forecast for Futura Medical.

Futura Medical plc (LON:FUM) posted its quarterly earnings results on Wednesday, September, 16th. The company reported ($0.44) earnings per share (EPS) for the quarter.
View Futura Medical's earnings history.

Futura Medical's stock was trading at GBX 11.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FUM stock has increased by 256.9% and is now trading at GBX 39.70.
View which stocks have been most impacted by COVID-19.

1 equities research analysts have issued 1 year price objectives for Futura Medical's stock. Their forecasts range from GBX 102 to GBX 102. On average, they anticipate Futura Medical's share price to reach GBX 102 in the next year. This suggests a possible upside of 156.9% from the stock's current price.
View analysts' price targets for Futura Medical or view top-rated stocks among Wall Street analysts.

Some companies that are related to Futura Medical include Beximco Pharmaceuticals (BXP), Sareum (SAR), ECO Animal Health Group (EAH), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Avivagen (VIV), N4 Pharma (N4P), Cathay International Holdings Limited (CTI.L) (CTI), Antisense Therapeutics (ANP), Bayer Aktiengesellschaft (BAYN), Mayne Pharma Group (MAYNF), Mayne Pharma Group (MYX), Medical Developments International (MVP), Opthea (OPT) and Otsuka (OTSKY).
View all of FUM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Futura Medical investors own include Indivior (INDV), Tullow Oil (TLW), Bigblu Broadband (BBB), Directa Plus (DCTA), Genel Energy (GENL), Lakehouse (LAKE), Petrel Resources (PET), The People's Operator (TPOP), (CITY.L) (CITY) and (PAYS.L) (PAYS).

Futura Medical trades on the London Stock Exchange (LON) under the ticker symbol "FUM."

Shares of FUM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

One share of FUM stock can currently be purchased for approximately GBX 39.70.

Futura Medical has a market capitalization of £113.97 million and generates £31,778.00 in revenue each year.

Futura Medical employs 13 workers across the globe.

The official website for Futura Medical is www.futuramedical.com.

Futura Medical is headquartered at 40 Surrey Technology Centre, Occam Road, GUILDFORD, GU2 7YG, United Kingdom.

Futura Medical's mailing address is 40 Surrey Technology Centre, Occam Road, GUILDFORD, GU2 7YG, United Kingdom. The company can be reached via phone at +44-1483-685670.